A REVIEW ON PLGA-BASED NANOPARTICLE FOR ZICONOTIDE
Main Article Content
Keywords
Targeted drug delivery, Nanoparticle, Neuropathic pain, Ziconotide, Complication of ziconotide delivery, PLGA-peptide Drug delivery.
Abstract
This article reviews the potential of poly (lactic-co-glycolic acid) (PLGA)-based nanoparticles for the delivery of ziconotide, a promising non-opioid peptide for neuropathic pain management. Ziconotide, derived from marine snail venom, is a selective N-type calcium channel blocker with significant analgesic potential but faces challenges like rapid degradation and the need for intrathecal administration due to poor blood-brain barrier permeability. PLGA offers a solution by enhancing drug stability, controlling release, and improving bioavailability. This review discusses formulation strategies, in vitro and in vivo studies, and future prospects for clinical application of PLGA-based ziconotide delivery systems.
References
1. Shinu P, Morsy MA, Nair AB, Mouslem AK, Venugopala KN, Goyal M, Bansal M, Jacob S, Deb PK. Novel therapies for the treatment of neuropathic pain: potential and pitfalls. Journal of Clinical Medicine. 2022 May 26;11(11):3002.
2. Choudhary S, Kaur R, Waziri A, Garg A, Kadian R, Alam MS. N-type calcium channel blockers: a new approach towards the treatment of chronic neuropathic pain. Exploration of Medicine. 2023 Feb 28;4(1):85-106.
3. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. The Lancet Neurology. 2010 Aug 1;9(8):807-19.
4. Barnes MP, Good DC. ERIC KERSTMAN, SANGMIN AHN, SREE BATTU, SHABREZ TARIQ, AND MARTIN GRABOIS. Neurological Rehabilitation. 2013 Jan 10:175.
5. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Current medicinal chemistry. 2004 Dec 1;11(23):3029-40.
6. Stepensky D. Pharmacokinetics of toxin-derived peptide drugs. Toxins. 2018 Nov 20;10(11):483.
7. Werbitzky O, Giraud M. Manufacturing of venom-derived therapeutic peptides..
8. Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert opinion on pharmacotherapy. 2008 Jun 1;9(9):1575-83.McGivern, J. G. (2007). Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatric Disease and Treatment, 3(1), 69–85.
9. McGivern, J. G. (2007). Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatric Disease and Treatment, 3(1), 69–85.
10. Khadam VK, Singh RP, Prajapati D, Yunus M, Prajapati B, Rai SK, Kumari P, Gogoi D. An Updated Comprehensive Review on Novel Drug Delivery Systems (NDDS) In the Pharmaceuticals. Asian Journal of Pharmaceutical Research and Development. 2024 Feb 15;12(1):55-64.
11. Kučuk N, Primožič M, Knez Ž, Leitgeb M. Sustainable biodegradable biopolymerbased nanoparticles for healthcare applications. International journal of molecular sciences. 2023 Feb 6;24(4):3188.
12. Murthy, S. K. (2007). Nanoparticles in modern medicine: State of the art and future challenges. International Journal of Nanomedicine, 2(2), 129–141.
13. Mir M, Ahmed N, ur Rehman A. Recent applications of PLGA based nanostructures in drug delivery. Colloids and Surfaces B: Biointerfaces. 2017 Nov 1;159:217-31.
14. Surya N, Bhattacharyya S. PLGA–the smart polymer for drug delivery. Pharmacy & Pharmacology. 2021 Oct 15;9(5):334-45.
15. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. Journal of controlled release. 2012 Jul 20;161(2):505-22.
16. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011 Aug 26;3(3):1377-97.
17. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced drug delivery reviews. 1997 Oct 13;28(1):5-24.
18. Liu G, McEnnis K. Glass Transition Temperature of PLGA Particles and the Influence on Drug Delivery Applications. Polymers. 2022; 14(5):993
19. Kapoor, D. N., Bhatia, A., Kaur, R., Sharma, R., Kaur, G., & Dhawan, S. (2015). PLGA: a Unique Polymer for Drug Delivery. Therapeutic Delivery, 6(1), 41–58.
20. Schmidtko A, Lötsch J, Freynhagen R, Geisslinger G. Ziconotide for treatment of severe chronic pain. The Lancet. 2010 May 1;375(9725):1569-77.
21. Mathur, V. S. (2000). Ziconotide: A new pharmacological class of drug for the management of pain. Seminars in Anesthesia, Perioperative Medicine and Pain, 19(2), 67–75.
22. Rauck, R. L., Wallace, M. S., Burton, A. W., Kapural, L., & North, J. M. (2009). Intrathecal Ziconotide for Neuropathic Pain: A Review. Pain Practice, 9(5), 327–337.
23. Wang, Y.-X., & Bowersox, S. S. (2006). Analgesic Properties of Ziconotide, a Selective Blocker of N-Type Neuronal Calcium Channels. CNS Drug Reviews, 6(1), 1–20.
24. Newcomb R, Abbruscato TJ, Singh T, Nadasdi L, Davis TP, Miljanich G. Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion. Peptides. 2000 Apr 1;21(4):491-501.
25. Penn RD, Paice JA. Adverse effects associated with the intrathecal administration of ziconotide. Pain. 2000 Mar 1;85(1):291-6.
26. Wu C, Mu H. Lipid and PLGA microparticles for sustained delivery of protein and peptide drugs. Pharmaceutical nanotechnology. 2020 Feb 1;8(1):22-32.
27. McGuire D, Bowersox S, Fellmann JD, Luther RR. Sympatholysis after neuronspecific, N-type, voltage-sensitive calcium channel blockade: first demonstration of Nchannel function in humans. Journal of cardiovascular pharmacology. 1997 Sep 1;30(3):400-3.
28. Bäckryd E. Do the potential benefits outweigh the risks? An update on the use of ziconotide in clinical practice. European Journal of Pain. 2018 Aug;22(7):1193-202.
29. Wallace MS, Rauck R, Fisher R, Charapata SG, Ellis D, Dissanayake S, Ziconotide 98022 Study Group. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesthesia & Analgesia. 2008 Feb 1;106(2):628-37.
30. Nair A, Poornachand A, Kodisharapu P. Ziconotide: Indications, adverse effects, and limitations in managing refractory chronic pain. Indian journal of palliative care. 2018;24(1).
31. Jain KK. An evaluation of intrathecal ziconotide for the treatment of chronic pain. Expert Opinion on Investigational Drugs. 2000 Oct 1;9(10):2403-10.
32. Rauck RL, Wallace MS, Burton AW, Kapural L, North JM. Intrathecal ziconotide for neuropathic pain: a review. Pain Practice. 2009 Sep;9(5):327-37.
33. Wermeling DP. Ziconotide, an intrathecally administered N‐type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2005 Aug;25(8):1084-94.
34. Brinzeu, A., Berthiller, J., Caillet, J.-B., Staquet, H., & Mertens, P. (2019). Ziconotide for spinal cord injury related pain. European Journal of Pain.
35. Allahyari M, Mohit E. Peptide/protein vaccine delivery system based on PLGA particles. Human vaccines & immunotherapeutics. 2016 Mar 3;12(3):806-28.
36. Ramchandar T, Rajkumar D. Design Prepare and characterization of Pregabalin loaded solid lipid Nanoparticles. Frontier Journal of Pharmaceutical Sciences and Research. 2023 Dec 27;6(3):37-41.
37. Salama AH, Salama AA, Elhabak M. Single step nanospray drying preparation technique of gabapentin-loaded nanoparticles-mediated brain delivery for effective treatment of PTZ-induced seizures. International Journal of Pharmaceutics. 2021 Jun 1;602:120604.
38. Wilson B, Lavanya Y, Priyadarshini SR, Ramasamy M, Jenita JL. Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. International journal of pharmaceutics. 2014 Oct 1;473(12):73-9.
39. Kim SI, Shin J, Tran Q, Park H, Kwon HH, Shin N, Hwang JA, Shin HJ, Lee J, Lee WH, Lee SY. Application of PLGA nanoparticles to enhance the action of duloxetine on microglia in neuropathic pain. Biomaterials Science. 2021;9(18):6295-307.
40. Khan I, Gothwal A, Sharma AK, Kesharwani P, Gupta L, Iyer AK, Gupta U. PLGA nanoparticles and their versatile role in anticancer drug delivery. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2016;33(2).
41. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide)(PLGA) devices. Biomaterials. 2000 Dec 1;21(23):2475-90.
42. Jyothi NV, Prasanna PM, Sakarkar SN, Prabha KS, Ramaiah PS, Srawan GY. Microencapsulation techniques, factors influencing encapsulation efficiency. Journal of microencapsulation. 2010 May 1;27(3):187-97.
43. Sasidharan S, Saudagar P. Encapsulation and delivery of antiparasitic drugs: a review. Encapsulation of Active Molecules and Their Delivery System. 2020 Jan 1:323-42.
44. Risch SJ. Encapsulation: overview of uses and techniques.
45. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine: nanotechnology, biology and medicine. 2010 Apr 1;6(2):324-33.
46. Vysloužil J, Doležel P, Kejdušová M, Mašková E, Mašek J, Lukáč R, Košťál V, Vetchý D, Dvořáčková K. The influence of different formulations and process parameters during the preparation of drug-loaded PLGA microspheres evaluated by multivariate data analysis. Acta Pharmaceutica. 2014 Dec 31;64(4):403-17.
47. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011 Aug 26;3(3):1377-97.
48. Chatterjee M, Chanda N. Formulation of PLGA nano-carriers: specialized modification for cancer therapeutic applications. Materials Advances. 2022;3(2):837-58.
49. Akl MA, Kartal-Hodzic A, Oksanen T, Ismael HR, Afouna MM, Yliperttula M, Samy AM, Viitala T. Factorial design formulation optimization and in vitro characterization of curcumin-loaded PLGA nanoparticles for colon delivery. Journal of Drug Delivery Science and Technology. 2016 Apr 1;32:10-20.
50. Jain S, Mittal A, K Jain A, R Mahajan R, Singh D. Cyclosporin A loaded PLGA nanoparticle: preparation, optimization, in-vitro characterization and stability studies. Current Nanoscience. 2010 Aug 1;6(4):422-31.
51. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Advanced drug delivery reviews. 2006 Dec 30;58(15):1688-713.
52. Holzer M, Vogel V, Mäntele W, Schwartz D, Haase W, Langer K. Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage. European Journal of Pharmaceutics and Biopharmaceutics. 2009 Jun 1;72(2):428-37.
53. Mittal P, Vardhan H, Ajmal G, Bonde GV, Kapoor R, Mittal A, Mishra B. Formulation, optimization, hemocompatibility and pharmacokinetic evaluation of PLGA nanoparticles containing paclitaxel. Drug development and industrial pharmacy. 2019 Mar 4;45(3):365-78.
54. Rai G, Gauba P, Dang S. Surface modified biodegradable nanoparticles of Gabapentin. An approach to increase cell uptake. Materials Today: Proceedings. 2023 Apr 25.
55. Afshari M, Derakhshandeh K, Hosseinzadeh L. Characterisation, cytotoxicity and apoptosis studies of methotrexate-loaded PLGA and PLGA-PEG nanoparticles. Journal of microencapsulation. 2014 May 1;31(3):239-45.
56. Salama AH, Salama AA, Elhabak M. Single step nanospray drying preparation technique of gabapentin-loaded nanoparticles-mediated brain delivery for effective treatment of PTZ-induced seizures. International Journal of Pharmaceutics. 2021 Jun 1;602:120604.
57. Prommer EE. Ziconotide: can we use it in palliative care?. American Journal of Hospice and Palliative Medicine®. 2005 Sep;22(5):369-74.
58. Yaksh TL, de Kater A, Dean R, Best BM, Miljanich GP. Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. Neuromodulation: Technology at the Neural Interface. 2012 Dec 1;15(6):508-19.
59. Pope JE, Deer TR. Intrathecal pharmacology update: novel dosing strategy for intrathecal monotherapy ziconotide on efficacy and sustainability. Neuromodulation: Technology at the Neural Interface. 2015 Jul 1;18(5):414-20.
60. Newcomb R, Abbruscato TJ, Singh T, Nadasdi L, Davis TP, Miljanich G. Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion. Peptides. 2000 Apr 1;21(4):491-501.
61. Wermeling, D. P. (2005). Ziconotide, an Intrathecally Administered N-Type Calcium Channel Antagonist for the Treatment of Chronic Pain. Pharmacotherapy, 25(8), 1084– 1094.
62. Klotz U. Ziconotide-a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain-a short review. International Journal of Clinical Pharmacology & Therapeutics. 2006 Oct 1;44(10).
63. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS: A Randomized Controlled Trial. JAMA. 2004;291(1):63–70.
64. Rauck RL, Wallace MS, Leong MS, MineHart M, Webster LR, Charapata SG, Abraham JE, Buffington DE, Ellis D, Kartzinel R, Ziconotide 301 Study Group. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. Journal of pain and symptom management. 2006 May 1;31(5):393-406.
65. Rauck RL, Wallace MS, Burton AW, Kapural L, North JM. Intrathecal ziconotide for neuropathic pain: a review. Pain Practice. 2009 Sep;9(5):327-37.
66. G.A. Hodge, D.M. Bowman, A.D. Maynard (Eds.), International Handbook on Regulating Nanotechnologies, Edward Elgar Publishing Limited, Northampton, MA, USA (2010), pp. 291-320
67. Ehmann F, Sakai-Kato K, Duncan R. Hernan Perez de la Ossa D, Pita R, Vidal JM, et al. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (Lond). 2013 May;8(5):849-56.
68. Duncan R, Gaspar R. Nanomedicine (s) under the microscope. Molecular pharmaceutics. 2011 Dec 5;8(6):2101-41.
69. Dobrovolskaia MA, McNeil SE. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. Journal of controlled release. 2013 Dec 10;172(2):456-66.
70. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Advanced drug delivery reviews. 2009 Jun 21;61(6):428-37.
71. Hafner A, Lovrić J, Lakoš GP, Pepić I. Nanotherapeutics in the EU: an overview on current state and future directions. International journal of nanomedicine. 2014 Feb 19:1005-23.
72. Demetzos C, Pippa N. Fractal geometry as a new approach for proving nanosimilarity: a reflection note. International Journal of Pharmaceutics. 2015 Apr 10;483(1-2):1-5.
73. Rayate YT, Yadav AR, Mohite SK. Novel Drug Delivery systems and its future prospects. World J Appl Pharm. 2023 Jan;1(1):14-9.
74. Awasthi A, Paul P, Mir MS, Singh SK, Dua K. Novel Drug Delivery Systems in Colorectal Cancer: Advances and Future Prospects. Pathology-Research and Practice. 2024 Aug 21:155546.
75. Narang A, Chang RK, Hussain MA. Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. Journal of pharmaceutical sciences. 2013 Nov 1;102(11):3867-82.
2. Choudhary S, Kaur R, Waziri A, Garg A, Kadian R, Alam MS. N-type calcium channel blockers: a new approach towards the treatment of chronic neuropathic pain. Exploration of Medicine. 2023 Feb 28;4(1):85-106.
3. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. The Lancet Neurology. 2010 Aug 1;9(8):807-19.
4. Barnes MP, Good DC. ERIC KERSTMAN, SANGMIN AHN, SREE BATTU, SHABREZ TARIQ, AND MARTIN GRABOIS. Neurological Rehabilitation. 2013 Jan 10:175.
5. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Current medicinal chemistry. 2004 Dec 1;11(23):3029-40.
6. Stepensky D. Pharmacokinetics of toxin-derived peptide drugs. Toxins. 2018 Nov 20;10(11):483.
7. Werbitzky O, Giraud M. Manufacturing of venom-derived therapeutic peptides..
8. Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert opinion on pharmacotherapy. 2008 Jun 1;9(9):1575-83.McGivern, J. G. (2007). Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatric Disease and Treatment, 3(1), 69–85.
9. McGivern, J. G. (2007). Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatric Disease and Treatment, 3(1), 69–85.
10. Khadam VK, Singh RP, Prajapati D, Yunus M, Prajapati B, Rai SK, Kumari P, Gogoi D. An Updated Comprehensive Review on Novel Drug Delivery Systems (NDDS) In the Pharmaceuticals. Asian Journal of Pharmaceutical Research and Development. 2024 Feb 15;12(1):55-64.
11. Kučuk N, Primožič M, Knez Ž, Leitgeb M. Sustainable biodegradable biopolymerbased nanoparticles for healthcare applications. International journal of molecular sciences. 2023 Feb 6;24(4):3188.
12. Murthy, S. K. (2007). Nanoparticles in modern medicine: State of the art and future challenges. International Journal of Nanomedicine, 2(2), 129–141.
13. Mir M, Ahmed N, ur Rehman A. Recent applications of PLGA based nanostructures in drug delivery. Colloids and Surfaces B: Biointerfaces. 2017 Nov 1;159:217-31.
14. Surya N, Bhattacharyya S. PLGA–the smart polymer for drug delivery. Pharmacy & Pharmacology. 2021 Oct 15;9(5):334-45.
15. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. Journal of controlled release. 2012 Jul 20;161(2):505-22.
16. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011 Aug 26;3(3):1377-97.
17. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced drug delivery reviews. 1997 Oct 13;28(1):5-24.
18. Liu G, McEnnis K. Glass Transition Temperature of PLGA Particles and the Influence on Drug Delivery Applications. Polymers. 2022; 14(5):993
19. Kapoor, D. N., Bhatia, A., Kaur, R., Sharma, R., Kaur, G., & Dhawan, S. (2015). PLGA: a Unique Polymer for Drug Delivery. Therapeutic Delivery, 6(1), 41–58.
20. Schmidtko A, Lötsch J, Freynhagen R, Geisslinger G. Ziconotide for treatment of severe chronic pain. The Lancet. 2010 May 1;375(9725):1569-77.
21. Mathur, V. S. (2000). Ziconotide: A new pharmacological class of drug for the management of pain. Seminars in Anesthesia, Perioperative Medicine and Pain, 19(2), 67–75.
22. Rauck, R. L., Wallace, M. S., Burton, A. W., Kapural, L., & North, J. M. (2009). Intrathecal Ziconotide for Neuropathic Pain: A Review. Pain Practice, 9(5), 327–337.
23. Wang, Y.-X., & Bowersox, S. S. (2006). Analgesic Properties of Ziconotide, a Selective Blocker of N-Type Neuronal Calcium Channels. CNS Drug Reviews, 6(1), 1–20.
24. Newcomb R, Abbruscato TJ, Singh T, Nadasdi L, Davis TP, Miljanich G. Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion. Peptides. 2000 Apr 1;21(4):491-501.
25. Penn RD, Paice JA. Adverse effects associated with the intrathecal administration of ziconotide. Pain. 2000 Mar 1;85(1):291-6.
26. Wu C, Mu H. Lipid and PLGA microparticles for sustained delivery of protein and peptide drugs. Pharmaceutical nanotechnology. 2020 Feb 1;8(1):22-32.
27. McGuire D, Bowersox S, Fellmann JD, Luther RR. Sympatholysis after neuronspecific, N-type, voltage-sensitive calcium channel blockade: first demonstration of Nchannel function in humans. Journal of cardiovascular pharmacology. 1997 Sep 1;30(3):400-3.
28. Bäckryd E. Do the potential benefits outweigh the risks? An update on the use of ziconotide in clinical practice. European Journal of Pain. 2018 Aug;22(7):1193-202.
29. Wallace MS, Rauck R, Fisher R, Charapata SG, Ellis D, Dissanayake S, Ziconotide 98022 Study Group. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesthesia & Analgesia. 2008 Feb 1;106(2):628-37.
30. Nair A, Poornachand A, Kodisharapu P. Ziconotide: Indications, adverse effects, and limitations in managing refractory chronic pain. Indian journal of palliative care. 2018;24(1).
31. Jain KK. An evaluation of intrathecal ziconotide for the treatment of chronic pain. Expert Opinion on Investigational Drugs. 2000 Oct 1;9(10):2403-10.
32. Rauck RL, Wallace MS, Burton AW, Kapural L, North JM. Intrathecal ziconotide for neuropathic pain: a review. Pain Practice. 2009 Sep;9(5):327-37.
33. Wermeling DP. Ziconotide, an intrathecally administered N‐type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2005 Aug;25(8):1084-94.
34. Brinzeu, A., Berthiller, J., Caillet, J.-B., Staquet, H., & Mertens, P. (2019). Ziconotide for spinal cord injury related pain. European Journal of Pain.
35. Allahyari M, Mohit E. Peptide/protein vaccine delivery system based on PLGA particles. Human vaccines & immunotherapeutics. 2016 Mar 3;12(3):806-28.
36. Ramchandar T, Rajkumar D. Design Prepare and characterization of Pregabalin loaded solid lipid Nanoparticles. Frontier Journal of Pharmaceutical Sciences and Research. 2023 Dec 27;6(3):37-41.
37. Salama AH, Salama AA, Elhabak M. Single step nanospray drying preparation technique of gabapentin-loaded nanoparticles-mediated brain delivery for effective treatment of PTZ-induced seizures. International Journal of Pharmaceutics. 2021 Jun 1;602:120604.
38. Wilson B, Lavanya Y, Priyadarshini SR, Ramasamy M, Jenita JL. Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. International journal of pharmaceutics. 2014 Oct 1;473(12):73-9.
39. Kim SI, Shin J, Tran Q, Park H, Kwon HH, Shin N, Hwang JA, Shin HJ, Lee J, Lee WH, Lee SY. Application of PLGA nanoparticles to enhance the action of duloxetine on microglia in neuropathic pain. Biomaterials Science. 2021;9(18):6295-307.
40. Khan I, Gothwal A, Sharma AK, Kesharwani P, Gupta L, Iyer AK, Gupta U. PLGA nanoparticles and their versatile role in anticancer drug delivery. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2016;33(2).
41. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide)(PLGA) devices. Biomaterials. 2000 Dec 1;21(23):2475-90.
42. Jyothi NV, Prasanna PM, Sakarkar SN, Prabha KS, Ramaiah PS, Srawan GY. Microencapsulation techniques, factors influencing encapsulation efficiency. Journal of microencapsulation. 2010 May 1;27(3):187-97.
43. Sasidharan S, Saudagar P. Encapsulation and delivery of antiparasitic drugs: a review. Encapsulation of Active Molecules and Their Delivery System. 2020 Jan 1:323-42.
44. Risch SJ. Encapsulation: overview of uses and techniques.
45. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine: nanotechnology, biology and medicine. 2010 Apr 1;6(2):324-33.
46. Vysloužil J, Doležel P, Kejdušová M, Mašková E, Mašek J, Lukáč R, Košťál V, Vetchý D, Dvořáčková K. The influence of different formulations and process parameters during the preparation of drug-loaded PLGA microspheres evaluated by multivariate data analysis. Acta Pharmaceutica. 2014 Dec 31;64(4):403-17.
47. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011 Aug 26;3(3):1377-97.
48. Chatterjee M, Chanda N. Formulation of PLGA nano-carriers: specialized modification for cancer therapeutic applications. Materials Advances. 2022;3(2):837-58.
49. Akl MA, Kartal-Hodzic A, Oksanen T, Ismael HR, Afouna MM, Yliperttula M, Samy AM, Viitala T. Factorial design formulation optimization and in vitro characterization of curcumin-loaded PLGA nanoparticles for colon delivery. Journal of Drug Delivery Science and Technology. 2016 Apr 1;32:10-20.
50. Jain S, Mittal A, K Jain A, R Mahajan R, Singh D. Cyclosporin A loaded PLGA nanoparticle: preparation, optimization, in-vitro characterization and stability studies. Current Nanoscience. 2010 Aug 1;6(4):422-31.
51. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Advanced drug delivery reviews. 2006 Dec 30;58(15):1688-713.
52. Holzer M, Vogel V, Mäntele W, Schwartz D, Haase W, Langer K. Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage. European Journal of Pharmaceutics and Biopharmaceutics. 2009 Jun 1;72(2):428-37.
53. Mittal P, Vardhan H, Ajmal G, Bonde GV, Kapoor R, Mittal A, Mishra B. Formulation, optimization, hemocompatibility and pharmacokinetic evaluation of PLGA nanoparticles containing paclitaxel. Drug development and industrial pharmacy. 2019 Mar 4;45(3):365-78.
54. Rai G, Gauba P, Dang S. Surface modified biodegradable nanoparticles of Gabapentin. An approach to increase cell uptake. Materials Today: Proceedings. 2023 Apr 25.
55. Afshari M, Derakhshandeh K, Hosseinzadeh L. Characterisation, cytotoxicity and apoptosis studies of methotrexate-loaded PLGA and PLGA-PEG nanoparticles. Journal of microencapsulation. 2014 May 1;31(3):239-45.
56. Salama AH, Salama AA, Elhabak M. Single step nanospray drying preparation technique of gabapentin-loaded nanoparticles-mediated brain delivery for effective treatment of PTZ-induced seizures. International Journal of Pharmaceutics. 2021 Jun 1;602:120604.
57. Prommer EE. Ziconotide: can we use it in palliative care?. American Journal of Hospice and Palliative Medicine®. 2005 Sep;22(5):369-74.
58. Yaksh TL, de Kater A, Dean R, Best BM, Miljanich GP. Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. Neuromodulation: Technology at the Neural Interface. 2012 Dec 1;15(6):508-19.
59. Pope JE, Deer TR. Intrathecal pharmacology update: novel dosing strategy for intrathecal monotherapy ziconotide on efficacy and sustainability. Neuromodulation: Technology at the Neural Interface. 2015 Jul 1;18(5):414-20.
60. Newcomb R, Abbruscato TJ, Singh T, Nadasdi L, Davis TP, Miljanich G. Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion. Peptides. 2000 Apr 1;21(4):491-501.
61. Wermeling, D. P. (2005). Ziconotide, an Intrathecally Administered N-Type Calcium Channel Antagonist for the Treatment of Chronic Pain. Pharmacotherapy, 25(8), 1084– 1094.
62. Klotz U. Ziconotide-a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain-a short review. International Journal of Clinical Pharmacology & Therapeutics. 2006 Oct 1;44(10).
63. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS: A Randomized Controlled Trial. JAMA. 2004;291(1):63–70.
64. Rauck RL, Wallace MS, Leong MS, MineHart M, Webster LR, Charapata SG, Abraham JE, Buffington DE, Ellis D, Kartzinel R, Ziconotide 301 Study Group. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. Journal of pain and symptom management. 2006 May 1;31(5):393-406.
65. Rauck RL, Wallace MS, Burton AW, Kapural L, North JM. Intrathecal ziconotide for neuropathic pain: a review. Pain Practice. 2009 Sep;9(5):327-37.
66. G.A. Hodge, D.M. Bowman, A.D. Maynard (Eds.), International Handbook on Regulating Nanotechnologies, Edward Elgar Publishing Limited, Northampton, MA, USA (2010), pp. 291-320
67. Ehmann F, Sakai-Kato K, Duncan R. Hernan Perez de la Ossa D, Pita R, Vidal JM, et al. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (Lond). 2013 May;8(5):849-56.
68. Duncan R, Gaspar R. Nanomedicine (s) under the microscope. Molecular pharmaceutics. 2011 Dec 5;8(6):2101-41.
69. Dobrovolskaia MA, McNeil SE. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. Journal of controlled release. 2013 Dec 10;172(2):456-66.
70. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Advanced drug delivery reviews. 2009 Jun 21;61(6):428-37.
71. Hafner A, Lovrić J, Lakoš GP, Pepić I. Nanotherapeutics in the EU: an overview on current state and future directions. International journal of nanomedicine. 2014 Feb 19:1005-23.
72. Demetzos C, Pippa N. Fractal geometry as a new approach for proving nanosimilarity: a reflection note. International Journal of Pharmaceutics. 2015 Apr 10;483(1-2):1-5.
73. Rayate YT, Yadav AR, Mohite SK. Novel Drug Delivery systems and its future prospects. World J Appl Pharm. 2023 Jan;1(1):14-9.
74. Awasthi A, Paul P, Mir MS, Singh SK, Dua K. Novel Drug Delivery Systems in Colorectal Cancer: Advances and Future Prospects. Pathology-Research and Practice. 2024 Aug 21:155546.
75. Narang A, Chang RK, Hussain MA. Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. Journal of pharmaceutical sciences. 2013 Nov 1;102(11):3867-82.
Article Sidebar
Published
Dec 11, 2024
Article Details
How to Cite
Mohit S Pillai, Ms. Krupa Vyas, & Dr. Pragnesh Patani. (2024). A REVIEW ON PLGA-BASED NANOPARTICLE FOR ZICONOTIDE. Journal of Population Therapeutics and Clinical Pharmacology, 31(11), 939-952. https://doi.org/10.53555/bfk9yg26
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Mohit S Pillai
Student, Khyati College of Pharmacy, Palodia, Ahmedabad.
Ms. Krupa Vyas
Assistant Professor, Khyati College of Pharmacy, Palodia, Ahmedabad
Dr. Pragnesh Patani
Principal and Professor, Khyati College of Pharmacy, Palodia, Ahmedabad
How to Cite
Mohit S Pillai, Ms. Krupa Vyas, & Dr. Pragnesh Patani. (2024). A REVIEW ON PLGA-BASED NANOPARTICLE FOR ZICONOTIDE. Journal of Population Therapeutics and Clinical Pharmacology, 31(11), 939-952. https://doi.org/10.53555/bfk9yg26